This guideline was developed to outline the management recommendations for patients with cholangiocarcinoma and adenocarcinoma of the gallbladder. For specific recommendations for the management of malignant biliary obstruction, please refer to the Malignant Biliary Obstruction clinical practice guideline. Isoniazid, primary sclerosing cholangitis, choledochal cysts, anomalous junction of the pancreaticobiliary duct, Salmonella or Opisthorchis infection) • Local extension is facilitated by the gallbladder's lack of a muscularis mucosa and submucosa, and by its direct venous drainage through the liver parenchyma to the hepatic veins. It may disseminate along the cystic duct, as well as by hematogenous, perineural, and intra-peritoneal spread.
• Present as a solid mass and/or an infiltrative lesion.
• Categorized by intra-hepatic (10%), peri-hilar (60%), or distal extra-hepatic (30%) location.
• Risk factors include · Primary sclerosing cholangitis · Chronic inflammation or infection (e.g.: Clonorchis or Opisthorchis infection, choledochal cysts) · Age · Cirrhosis of any etiology, including viral hepatitis · Exposures to dioxin, vinyl chloride, and nitrosamines • Tumors grow by infiltration along biliary ducts, invasion into perineural and vascular spaces, or direct extension into adjacent structures.
GUIDELINE QUESTIONS
• What are the management recommendations for adult patients with localized and potentially resectable cancers of the biliary tree or gallbladder? • What are the management recommendations for adult patients with unresectable or metastatic cancers of the biliary tree or gallbladder? 
SEARCH STRATEGY
This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team's interpretation of the data. The 2016 update did not necessitate a full literature review and focused on adjuvant therapy. Recommendations were modified based on a consensus discussion at the 2015 Annual Gastrointestinal Tumour Team Meeting.
TARGET POPULATION
The recommendations outlined in this guideline apply to adults over the age of 18 years with cancers of the biliary tree and gallbladder. Different principles may apply to pediatric patients.
RECOMMENDATIONS AND DISCUSSION

Suggested Diagnostic Work-Up
A complete diagnostic work-up provides the multidisciplinary team with the necessary information required to define and offer the optimal care to patients with biliary cancers. The multidisciplinary team should be composed of radiologists, general and hepatobiliary surgeons, gastroenterologists and hepatologists, and oncologists. The diagnostic work-up should evaluate the liver for local and vascular extension/invasion.
Unresectable or metastatic disease represents an incurable situation for which palliative options should be considered.
An abdominal ultrasound confirms biliary duct dilation, localizes the site of obstruction, and excludes gallstones. A three-phase CT scan detects the disease, locates the level of biliary obstruction, and identifies any regional lymphadenopathy or metastatic disease.
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Proximal Cholangiocarcinoma and Gallbladder Carcinoma:
To establish resectability, the diagnostic work-up should define the proximal extent of the tumor in both lobes of the liver. Endoechosonography obtains a biopsy to distinguish between a benign stricture and a cholangiocarcinoma.
Distal Cholangiocarcinoma:
ERCP is a useful procedure in patients with distal cholangiocarcinomas. MRCP should be reserved for those patients in whom biliary drainage is not imminently required. The other staging procedures are the same as for proximal cholangiocarcinomas. Stage IVB Tany As described above N2 Non-regional lymph nodes M0 Absent Tany As described above Nany As described above M1 Present * Adjacent structures include colon, stomach, duodenum, pancreas, omentum, or abdominal wall.
Staging
§ Regional (N1) refers to the hilar lymph nodes (adjacent to cystic duct, bile duct hepatic artery, and portal vein. Non-regional (N2) refers to the lymph nodes in the celiac, peri-duodenal, peri-pancreatic, or superior mesenteric regions. 
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Goals of Therapy
To render the patient free of disease, to delay or prevent recurrence, and to improve or prolong survival.
Recommendations
All patients should be referred for a multidisciplinary assessment. All patients without overt metastatic disease should be referred to a hepatobiliary surgeon or surgical oncologist for assessment of resectability. 
•
If a gallbladder cancer is suspected pre-operatively, an attempt at laparoscopic resection is contraindicated. Refer patients to a hepatobiliary surgeon or surgical oncologist.
For patients with Tis-1aN0M0 disease identified incidentally at pathologic review of the cholecystectomy specimen, no further therapy is necessary provided an "R0" margin (microscopically negative) is achieved. [6] [7] [8] Resection of the laparoscopic port sites is recommended.
9-11
• When an "R0" (microscopically negative) margin is anticipated for T2-3N0M0 disease, a hepatobiliary surgeon or surgical oncologist may consider a partial hepatectomy with peri-portal lymph node dissection. Consider a laparoscopy to exclude previously unrecognized peritoneal metastases before proceeding to laparotomy. 12 The role of radical surgery is controversial for T1b tumors. Cholangiocarcinoma:
13-15
• Assessment for resectability should precede instrumentation (e.g.: ERCP, PTC).
•
Resectability depends upon the extent of tumor within the biliary tree and hepatic parenchyma as well as the absence of invasion into the vasculature, unilateral hepatic lobar atrophy with contralateral extension of disease into the segmental bile ducts, regional lymphadenopathy, and metastatic disease.
For tumors that involve the confluence of the bile ducts, an "R0" resection involves excision of the tumor, regional lymphadenectomy, cholecystectomy, and (often) partial hepatectomy (possibly to include the caudate lobe).
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• When an "R0" (microscopically negative) margin is anticipated, lesions distal to the cystic duct require a pancreaticoduodenectomy.
•
It is unclear whether adjuvant therapy confers a benefit for either adenocarcinoma of the gallbladder or cholangiocarcinoma.
16
• Adjuvant therapy may be considered in select patients. Discussion in multidisciplinary rounds is encouraged.
Unresectable or Metastatic Disease
•
Offer palliative maneuvers to maintain and/or improve quality of life. Once resection has been deemed impossible, relieve biliary obstruction (if possible) by stent placement via either ERCP or PTC. In certain circumstances, radiotherapy or palliative surgery may be considered.
In patients with adequate biliary drainage, acceptable liver and kidney function, and a reasonable performance status (ECOG ≤ 2), the administration of up to eight twenty-one day cycles of Cisplatin 25 mg/m 2 IV and Gemcitabine 1,000 mg/m 2 IV on days one and eight prolongs progression-free survival from 6.5 months to 8.4 months (HR 0.72, CI95% 0.57-0.90, p = 0.003) and overall survival from 8.3 months to 11.7 months (HR 0.70, CI95% 0.54-0.89, p = 0.002) when compared to Gemcitabine alone. 
DISSEMINATION
• Present the guideline at the local and provincial tumour team meetings and weekly rounds.
• Post the guideline on the Alberta Health Services website.
• Send an electronic notification of the new guideline to all members of CancerControl Alberta.
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MAINTENANCE
A formal review of the guideline will be conducted at the Annual Provincial Meeting in 2017. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.
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